Press Releases

Date Title and Summary
Toggle Summary Capnia Awarded NIH Grant to Develop Sickle Cell Anemia Screening in Developing Countries
Phase 1 SBIR Grant Supported by Scientific Data Recently Published in Journal Pediatric Blood & Cancer REDWOOD CITY, Calif. , April 6, 2015 (GLOBE NEWSWIRE) -- Capnia, Inc. (Nasdaq:CAPN), focused on the development of novel products based on its proprietary technologies for precision metering
Toggle Summary Capnia Reports Fourth Quarter and Full Year 2014 Financial Results
REDWOOD CITY, Calif. , March 10, 2015 (GLOBE NEWSWIRE) -- Capnia, Inc. (Nasdaq:CAPN), focused on the development of novel products based on its proprietary technologies for precision metering of gas flow, today announced financial results for the fourth quarter and twelve months ended December 31,
Toggle Summary Capnia Announces Receipt of $3.6 Million From Series B Warrant Exercise and Issuance of Series C Warrants
REDWOOD CITY, Calif. , March 5, 2015 (GLOBE NEWSWIRE) -- Capnia, Inc. (Nasdaq:CAPN), focused on the development of novel products based on its proprietary technologies for precision metering of gas flow, today announced the closing of a privately negotiated transaction (the "Private Transaction")
Toggle Summary Capnia Announces First U.S. Commercial Sales of CoSense(R)
REDWOOD CITY, Calif. , Feb. 17, 2015 (GLOBE NEWSWIRE) -- Capnia, Inc. (Nasdaq:CAPN), focused on the development of novel products based on its proprietary technologies for precision metering of gas flow, today announced the first U.S. commercial sales of the Company's CoSense End-Tidal Carbon
Toggle Summary Capnia Announces Publication of CoSense® Scientific Data in the Journal Blood Cells, Molecules and Diseases
REDWOOD CITY, Calif. , Jan. 28, 2015 /PRNewswire/ --  Capnia, Inc. (NASDAQ: CAPN), focused on the development of novel diagnostics and therapeutics based on its proprietary technologies for precision metering of gas flow, today announced a paper, titled "End-tidal carbon monoxide as an indicator of
Toggle Summary Capnia Applies for Orphan Drug Designation in the U.S. for the Treatment of Trigeminal Neuralgia
REDWOOD CITY, Calif. , Jan. 8, 2015 / PRNewswire / -- Capnia, Inc. (NASDAQ: CAPN), focused on the development of novel diagnostics and therapeutics based on its proprietary technologies for precision metering of gas flow, today announced that it has submitted an application to the U.S.
Toggle Summary Capnia and Clinvest® Partner to Develop Cluster Headache Therapeutic
REDWOOD CITY, Calif. , Jan. 6, 2015 / PRNewswire / -- Capnia, Inc. (NASDAQ: CAPN), focused on the development of novel diagnostics and therapeutics based on its proprietary technologies for precision metering of gas flow, and Clinvest®, a research organization dedicated to the advancement of
Toggle Summary Capnia to Present at OneMedForum 2015
REDWOOD CITY, Calif. , Jan. 5, 2015 / PRNewswire / -- Capnia, Inc. (NASDAQ: CAPN), focused on the development of novel diagnostics and therapeutics based on its proprietary technologies for precision metering of gas flow, today announced that Anish Bhatnagar , M.D., Chief Executive Officer, will
Toggle Summary Capnia Reports Third Quarter 2014 Financial Results
REDWOOD CITY, Calif. , Dec. 18, 2014 / PRNewswire / -- Capnia, Inc. (NASDAQ: CAPN), focused on the development of medical diagnostics based on its proprietary Sensalyze™ Technology Platform for precision metering of gas flow, today announced financial results for the third quarter and nine months
Toggle Summary Capnia Presents CoSense® Data at the 2014 American Society of Hematology Annual Meeting
REDWOOD CITY, Calif. , Dec. 8, 2014 / PRNewswire / -- Capnia, Inc. (NASDAQ: CAPN), focused on the development of medical diagnostics based on its proprietary Sensalyze™ technology for precision metering of gas flow, today announced a poster presentation at the 2014 American Society of Hematology